Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B 006

Drug Profile

B 006

Alternative Names: Anti-CD30 monoclonal antibody-MCC-DM1 conjugate; anti-CD30-MCC-DM1; B006; Recombinant anti-CD30 humanised monoclonal antibody conjugate

Latest Information Update: 26 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Pharmaceuticals Holding
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Anaplastic large cell lymphoma; Hodgkin's disease
  • Preclinical Cutaneous T-cell lymphoma

Most Recent Events

  • 30 Mar 2022 Shanghai Pharmaceuticals has independent intellectual property rights for B 006
  • 30 Mar 2022 Phase-I clinical trials in Anaplastic large cell lymphoma in China (Parenteral), before March 2022
  • 30 Mar 2022 Phase-I clinical trials in Hodgkin's disease in China (Parenteral), before March 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top